Kim et al. demonstrated that EMPA exerts cardioprotective effects by mitigating NLRP3 inflammasome activation, increasing cardiac ketone oxidation, and decreasing serum insulin levels in T2D and CVD patients [73]. The gene discussed is INS; the disease is type 2 diabetes mellitus.